Interventional Neurology: Carotid Artery Stents and Embolic Protection Systems
Ischemic stroke remains a leading cause of death worldwide, with nearly 10 million new cases per year and a prevalence of more than 75 million. Carotid artery stenting (CAS) is a less-invasive treatment compared to open surgery and extends treatment to a wider group of patients including those who are poor candidates for open surgery. Embolic protection plays an important role in a CAS procedure, and most CAS manufacturers have developed embolic protection devices (EPDs) for use in conjunction with their CAS systems. In 2020, the global market for CAS systems and EPDs totaled nearly $350m. During the forecast period covered by this report, total sales are projected to expand at a CAGR of more than 9%, exceeding $530m in 2025. 2020 sales reflect a significant drop over 2019, as the COVID-19 pandemic had a profound impact on procedure volumes in the first half of 2020. A large boost is expected in 2021, with a return to more typical market patterns for the remainder of the forecast period. The leading suppliers of CAS systems and EPDs include Abbott and Silk Road Medical, with nearly 70% of the market combined. Other suppliers include Cordis, Medtronic, and Boston Scientific. This analysis provides a clinical overview and prevalence data for carotid artery stenosis, product portfolios offered by leading manufacturers as well as emerging products, and in-depth market and competitive analyses of the CAS system and EPD markets. Forecasts are provided for 2020–25 for the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Rest of World markets.